Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study

Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study

AimsThis three-year follow-up study aimed to elucidate whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) have any protection against diabetic neuropathy and nephropathy in patients with type 2 diabetes via reducing variability in glycemia and extraglycemic factors or their averages.Methods...

Full description

Bibliographic Details
Main Authors: Fukashi Ishibashi, Aiko Kosaka, Mitra Tavakoli
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Endocrinology
Subjects:
SGLT2i
diabetic microvascular complication
protection against neuropathy and nephropathy
glycemic variability
extraglycemic factors
modest glycemic control
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.864332/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.864332/full

Similar Items